Released: July 16, 2018

Defense Health Program
Department of Defense Gulf War Illness Research Program
Funding Opportunities for Fiscal Year 2018 (FY18)

The FY18 Defense Appropriation provides $21 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support high-impact research that will identify effective treatments and accelerate their clinical application, identify objective markers for improved definition and diagnosis, and/or provide a better understanding of the pathobiology underlying the complex of Gulf War Illness symptoms. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the website in August 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.

The following mechanism is planned for release:

Award Mechanism Eligibility Key Mechanism Elements Funding
New Investigator Award PIs may apply under one of the following three eligibility categories:
  • Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.
  • Early-Career Investigator: Independent investigators within 5 years since their last training position.
  • New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research.
  • Submission of a Letter of Intent is required.
  • Encourages applications from early stage and established investigators new to the field of GWI research.
  • Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are encouraged.
  • Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
  • Studies that provide outcomes clearly translatable to clinical use are encouraged.
  • Clinical trials are not allowed.
  • The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
  • The maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022